SPY337.34+2.45 0.73%
DIA279.03+1.53 0.55%
IXIC11,298.71+131.20 1.17%

FDA Grants Orphan Drug Designation To Kadmon's Belumosudil For Treatment Of Systemic Sclerosis

NEW YORK, NY / ACCESSWIRE / September 8, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to belumosudil (KD025), the

· 09/08/2020 08:14

NEW YORK, NY / ACCESSWIRE / September 8, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to belumosudil (KD025), the Company's Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of systemic sclerosis (SSc). SSc is a chronic immune disorder characterized by fibrosis of the skin and internal organs, affecting approximately 75,000 to 100,000 people in the United States.